Foresight Diagnostics’ PhasED-Seq Circulating Tumor DNA Platform Demonstrates Highly Sensitive Minimal Residual Disease (MRD) Detection in B-Cell Lymphomas

AURORA, Colo., July 22, 2021 (GLOBE NEWSWIRE) -- Foresight Diagnostics today announced publication of studies demonstrating unprecedented analytical and clinical sensitivity of the Companys proprietary circulating tumor DNA (ctDNA) detection platform for minimal residual disease (MRD) detection in B-cell lymphomas.